SCHEMBL5116156

SCHEMBL5116156

Cc1csc2nc(-c3ccno3)nc(NCc3ccc4c(c3)OCO4)c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
TSHR P16473 4/20 0.43
MAPT P10636 4/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
TP53 P04637 1/20 0.43
HTT P42858 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PDE5A O76074 4/20 0.43
ESR1 P03372 1/20 0.42
LMNA P02545 2/20 0.41
MAPK1 P28482 2/20 0.41
USP2 O75604 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5125583 0.94 ESR1 (0.42) ALDH1A1TSHRMAPTKMT2AMEN1
SCHEMBL5118575 0.91 FAAH (0.39) ALDH1A1TSHRMAPTKMT2AMEN1
SCHEMBL7518212 0.86 FAAH (0.38) PDE5AESR1
SCHEMBL5130570 0.86 MAPT (0.48) ALDH1A1TSHRMAPTKMT2AMEN1
SCHEMBL7618896 0.85 LMNA (0.38) ALDH1A1MAPTHTTL3MBTL1ESR1
SCHEMBL5115505 0.85 ALDH1A1 (0.42) ALDH1A1TSHRMAPTKMT2AMEN1
SCHEMBL5117945 0.84 ESR1 (0.51) ALDH1A1MAPTKMT2AMEN1NPSR1
SCHEMBL5129214 0.84 ESR1 (0.49) ALDH1A1ESR1USP1WDR48SMN1; SMN2
SCHEMBL5125502 0.84 CHRM4 (0.42) ALDH1A1TSHRMAPTKMT2AMEN1
SCHEMBL5119670 0.83 HIF1A (0.46) ALDH1A1TSHRMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
EP-1685136-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 2006-08-02 EP disclosed
WO-2005047292-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 2005-05-26 WO disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed
EP-0920431-A1 THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 1999-06-09 EP disclosed
WO-1998006722-A1 THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 1998-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 ALDH1A1 1055/4885TSHR 1050/4885MAPT 2997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.